The leverage of the innovative therapy Jusvinza in seriously or critically ill patients with Covid-19 in which it is suspected or identified a hyper-inflammation stage, was released by the Center for Genetic Engineering and Biotechnology (CIGB) in its Twitter account.

Gramma newspaper highlights that the drug is prescribed for the treatment of patients with rheumatoid arthritis.

Might be of interest: Juzvinza will allow the treatment of rheumatoid arthritis and hyper-inflammation

https://lahabana.gob.cu/post_detalles/es/12925/jusvinza-permitira-tratar-la-artritis-reumatoide-y-la-hiperinflamacion

According to this media outlet, the drug, with innovative and safer principles is capable to induce regulative mechanisms of the immune system and does not cause immunosuppression due to its active ingredient is a synthetic peptide.  

It is also specified that its productive system is actually strong and it’s based on by intellectual property, which re-vindicates its design and the peptide formulation as for its application in the control of hyper-inflammation and the cytokine storm.

A report from the Presidency´s website stressed out that the molecule obtained and patented by the CIGB has already shown its benefits in the treatment of patients with Covid-19.

The Center for the State Control of Medicine, Equipment and Medical devices (CEDMED) granted the emergency Use clearance for this treatment. The decision was based on a concluded phase I trial and a clinical trial phase II in execution, both for the treatment of rheumatoid arthritis.

For this 2022, at a meeting with the first secretary of the Central Committee of the Party and President of the Republic, Miguel Díaz- Canel Bermudez, the researchers announced that the clinical trial phase III with Jusvinza might begin, during which 66 000 people are estimated to be treated , which represents the 50% of the reported patients with this disease in Cuba.

The drug is indicated to be used in hospitals and only in adult’s patients, because it has not been used in children, and for that reason it is not recommended to be used in pediatric.

Individuals with hyper-sensibility to any of the excipients of the formation are warned and must not be used in those who are being treated with other biological drugs, headed to the treatment of the cytokine storm.

Its use has not been evaluated in pregnant women and children.

Related info:

CEDMED autoriza el medicamento Jusvinza para uso de emergencia en el tratamiento a la Covid-19.